Biosimilar Switching Studies, Human Factors Analyses Are Flashpoints For Industry
Executive Summary
US FDA should offer more flexibility on endpoint in clinical switching studies for interchangeability, generic companies say in comments that also argue a draft guidance recommendation for human factors studies to compare use error rates between products is misplaced.
You may also be interested in...
Biosimilar Interchangeability Switching Studies May Use Foreign Comparators, US FDA Says
But scientific bridging required for non-US reference products might be more extensive than in other contexts, agency cautions; easing of the US comparator-only recommendation is one of several changes from the 2017 draft guidance that could make pursuing an interchangeability designation easier.
US Biosimilars: FDA Seeks To Build On Record Number Of Approvals, But Shutdown May Blunt Progress
Past year was the high-water mark for product approvals and launches, but complete response letters remain a frequent occurrence. FDA’s ability to deliver on its promise of further clarity on transition products, interchangeability and indication carve-outs/carve-ins may take a hit from the ongoing partial government shutdown. On the legal side, look for more patent settlements with staggered entry dates and new antitrust scrutiny.
Interchangeability Won’t Solve US Biosimilar Market’s Woes, FDA’s Gottlieb Says
FDA's Biosimilar Action Plan aims to boost approvals, but Commissioner Gottlieb says he's had a change of heart about how much impact an interchangeability designation can have on market uptake.